|
Apr 17
|
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
|
|
Mar 28
|
Alector Provides Executive Leadership Update
|
|
Feb 28
|
Alector Full Year 2024 Earnings: Beats Expectations
|
|
Feb 27
|
Q4 2024 Alector Inc Earnings Call
|
|
Feb 19
|
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
|
|
Feb 19
|
February 2025 US Penny Stocks With Promising Prospects
|